Treatment with Anti-EGF Ab Ameliorates Experimental Autoimmune Encephalomyelitis via Induction of Neurogenesis and Oligodendrogenesis

Abstract EN

Background.

The neural stem cells (NSCs) migrate to the damaged sites in multiple sclerosis (MS) and in experimental autoimmune encephalomyelitis (EAE).

However, the differentiation into neurons or oligodendrocytes is blocked.

Epidermal growth factor (EGF) stimulates NSC proliferation and mobilization to demyelinated lesions but also induces astrogenesis and glial scar.

Objective.

To examine the clinical and histopathological effects of EGF neutralization on EAE.

Methods.

EAE-induced SJL mice were intravenously treated with either anti-EGF neutralizing antibody (Ab) or isotype control or PBS.

On day 9 after immunization, 3 mice of each group were daily treated for 9 days with BrdU and then sacrificed for immunohistochemical analysis.

Results.

Treatment with anti-EGF Ab significantly ameliorated EAE symptoms during the second relapse.

Anti-EGF Ab induced a shift from BrdU+GFAP+ NSCs to BrdU+DCX+ neuroblasts in the subventricular zone (SVZ), increased BrdU+NeuN+ neurons in the granular cell layer of the dentate gyrus, and increased BrdU+O4+ oligodendrocytes in the SVZ.

There was no change in the inflammatory infiltrates in response to anti-EGF Ab.

Conclusions.

Therapy with anti-EGF Ab ameliorates EAE via induction of neurogenesis and oligodendrogenesis.

No immunosuppressive effect was found.

Further investigation is needed to support these notions of beneficial effect of anti-EGF Ab in MS.